Basic Information
| ID | DRAMP21381 |
|---|
| Sequence | aikirklfkkllr |
|---|
| Length | 13 |
|---|
| Name | SP1D * (De Novo Synthesis) |
|---|
| Source | synthetic construct |
|---|
| Activity | Antimicrobial, Antibacterial, Anti-Gram- |
|---|
| Pathogen | [Ref.31163671] Gram-negative bacteria:Escherichia coli ATCC 25922 (MIC=12.5–25 µg/mL) |
|---|
| Hemolytic Activity | [Ref.31163671] 10% hemolysis at 25–50 μg/mL against human blood cells. |
|---|
| Cytotoxicity | [Ref.31163671] The cell viability of Hepa 1-6 induced by SP1D is 80.4%, 102.0%, 81.8%, 81.8%, 74.3% and 66.2% at peptide concentrations of 3.125, 6.25, 12.5, 25, 50 and 100 μg/mL. |
|---|
| N-terminal Modification | Free |
|---|
| C-terminal Modification | Amidation |
|---|
| Linear/Cyclic/Branched | Linear |
|---|
| Uniprot |
|
|---|
| PDB |
|
|---|
| 3D View | |
|---|
| PDB Download | Download PDB Predicted by Alphafold2 |
|---|
| PubMed ID | 31163671 |
|---|
